The surgical treatment of cutaneous melanoma. by Arons, M. S.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 48, 417-422 (1975)
The Surgical Treatment of
Cutaneous Melanoma
MARVIN S. ARONS
Department ofSurgery, Section ofPlastic andReconstructiveSurgery,
Yale University SchoolofMedicine, and Two Church Street, South,
NewHaven, Connecticut 06519
Received August 8, 1975
INTRODUCTION
Most surgeons find security in performing a standardized procedure for a specific
type of disease process or tumor. Malignant melanoma has never lent itself to this
concept. However, the previous excessively evil reputation of malignant melanoma
has been brought into truer perspective by thehistologic staging ofthedisease (1-5).
It can be said that the microstaging of cutaneous melanomas has not only been
useful for predicting the incidence of eventual lymph node metastases and overall
prognosis but also has brought some surgical "order out ofchaos." The levels ofin-
vasion by melanoma now give the most information to the surgeon concerning
necessary extent ofsurgery and prognosis (4, 5).
SPECIFIC LESIONS
Frequently, the child or adult patient is seen by the surgeon for treatment after
biopsy by the referring physician. In these cases, the surgeon relies only on the
pathologic diagnosis and systemic examination. However, he must recognize not
only the clinical manifestations of cutaneous melanoma but other specific lesions
that may at times mimic the appearance ofmelanoma.
BenignJuvenile Melanoma
This lesion is usually a nonpigmented, pale red, papular lesion occurring before
puberty (6). In about 15% of cases, it is observed initially in adolescence or
adulthood and often is confused with a hemangioma (7). It is important to recognize
this benign lesion to avoid unnecessary radical operative procedures.
Blue Nevus
This is a firm, well-defined intradermal nodule composed ofdermal melanocytes.
Although malignant degeneration in blue nevi is rare, malignancy can occur in le-
sions that clinically resemble a blue nevus (8).
Halo Nevus
This term is used to describe a pigmented nevus surrounded by a zone or margin
ofdepigmented skin (9). It has a life history that includes centripetal extension ofthe
depigmented halo and the spontaneous disappearance of the nevus (10). Most com-
monly, this process is found on the trunk ofyoung Caucasians. It is postulated that
the depigmentation and disappearance of the nevus is based on an immunologic
reaction (11). No surgical treatment is required.
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Giant Pigmented Nevus
This is a congenital, pigmented hairy lesion that sometimes demonstrates a
tendency to occur in the distribution of dermatomes. It may occur in the bathing
trunk area, vest, sleeve, or in a stocking pattern. It most commonly occurs on the
head or pelvic areas. The risk of malignant degeneration in such lesions is well
known, and prophylactic resection and skin grafting are now considered mandatory
in order to prevent transformation into malignant melanoma (12-15). Because the
area encompassed by such lesions may be huge in comparison with the total surface
area of a child, staged excision and grafting may be required. It is important to
remove some margin of seemingly normal skin beyond that indicated by the
presence or absence ofpigment in these giant nevi because melanocyte proliferative
activity is frequently more extensive than is visually apparent. Retrospective studies
have shown the malignant potential of giant pigmented nevi varies from 2 to 42%
(13, 15).
Pigmented Nevion Palms andSoles
Routine excision of pigmented nevi in certain anatomic locations such as the
palms and soles has been advocated as a prophylactic measure in the prevention of
malignant melanoma. Pigmented palmar and plantar nevi do show proliferative
activity at the dermo-epidermal junction at a later age than nevi of other sites (6).
Their incidence increases progressively in the first two decades oflife, reaches a peak
in the third, declines thereafter and parallels the biologic life cycle ofthe nevus cell.
One study of 10,000 men revealed at least one pigmented nevus on the palms and
soles (or genitalia) of 14.9% of the patients (16). Routine excision ofpigmented nevi
on palms and soles is not practical because of the large volume of patients and
unwarranted because the progression to melanoma of these nevi has never been
proven conclusively (17).
Melanotic Freckle ofHutchinson (Lentigo Maligna)
Early in its biologic history, this pigmented skin tumor resembles a junctional
nevus but is characterized by continuing slow growth to form a patch of pig-
mentation ofvarying size. Characteristically, it occurs on the face, especially in the
malar region ofelderly patients (18). The pathologic difference between lentigo ma-
ligna and malignant melanoma isindefinite, and a change from the benign to the ma-
lignant state may take up to 40 yr (19-21). Biopsy of all lentigo maligna lesions is
mandatory. For dermatologic classification, lentigo maligna has also been referred
to as circumscribed precancerous melanoma (22-24).
Dermatologists have advised electrodesiccation and curettage for some of these
melanotic freckles, although a plastic surgeon would generally advise surgical
excision and primary closure if possible or closure with a full thickness re-
troauricular skin graft in an elderly patient. With more extensive involvement, espe-
cially on the face, three-dimensional excision (including depth) with an adequate
margin of normal skin is performed. If melanoma is evident, operative criteria are
those for other melanomas oflowergrade malignancy, Clinical Stage I, Level I (25).
In these cases, excision and full thickness skin grafting are advisable.
BIOPSY AND THE PROGNOSIS OF MALIGNANT MELANOMA
The question of manipulating a melanoma or any malignant type of tumor for
biopsy has always disturbed surgeons who feel local recurrence and distant
metastases increase from such a procedure. There have been too many arguments
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raised in the literature to mention concerning this dilemma, as well as the advan-
tages and disadvantages of excisional biopsies, total biopsies, and aspiration
biopsies. It has never been proven that cancer cells found in operative wound wash-
ings have been significant, and no definite link has ever been demonstrated between
biopsy and local recurrence, regional metastases, distant metastases, or survival
(26). For that matter, the finding of circulating tumor cells from many varieties of
tumors (including melanoma) also has never been correlated with local recurrence,
distant metastases, regional lymph node metastases, or survival (27).
Since the clinical diagnosis ofpigmented cutaneous lesions is often uncertain, even
with the expertise ofa specialist, pathologic diagnosis is essential in order to plan ap-
propriate surgical treatment. There is no evidence to indicate that even incomplete
removal of a malignant melanoma at any histologic level followed by definitive sur-
gery decreases the probability ofsurvival (28).
SPECIFIC SURGICAL TREATMENT
Wide excision of the cutaneous malignant melanoma and/or biopsy site with
coverage by a split thickness skin graft is the basic treatment procedure of choice.
The treatment of Hutchinson's freckle and its differentiation from histologic Level I
melanoma have already been noted. Sometimes the term superficial malignant
melanoma is applied to those cases in which invasion is limited to the upper third of
the dermis, Levels I and II (29). The procedure of choice for these cases is wide
excision and skin grafting with sufficient depth. Frozen sections can be most helpful
when the surgeon is working closely with a pathologist.
It is generally held that elective regional lymph node dissection in the treatment of
Stage I and Stage II cutaneous melanoma is not advantageous. However, there has
been a recent minority report that the inclusion of such an extended procedure
improves 5-yr survival (30).
The more important aspect of treatment should be adequate local excision.
Statistics have shown that the local recurrence rate of cutaneous melanoma
following limited excision is approximately 57% in contrast to a 3% local recurrence
following wide excision (31).
EXTENT OF RESECTION AND ROLE OF
REGIONAL LYMPHADENECTOMY
The incidence oflocal recurrence is higher when wide excision is not performed. In
those instances, about one-third of recurrences will appear in the scar, one-third will
be in the tissue between the primary tumor and the lymph nodes, and one-third will
appear as regional node metastases (32, 33). The general recommendations (34) in
regard to local excision are listed below.
1. Malignant melanomas should be excised with a normal margin of tissue that
extends about 6 cm beyond the edge of the lesion when anatomy permits. In some
critical facial areas, the margins obviously cannot be so generous.
2. The area of excision should be asymmetrical when possible so that the extra
"6normal tissue" contains thedraininglymphatics.
3. Excision should extend down to but not include the deep fascia, which is
thought to be a barrier of lymphatic drainage from the subcutaneous tissue to a
deeper lymphatic.
Alluded to before in this discussion has been the controversy surrounding the
value of lymph node dissection. Therapeutic lymph node dissection means removal
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of lymph nodes thought to be clinically involved. Prophylactic or elective lymph
node dissection means removal of lymph nodes thought clinically uninvolved.
Literally dozens ofstudies have explored this subject but without really valid conclu-
sions, and so the inclusion of regional lymph node dissection electively or thera-
peutically after wide excision with skin grafting ofthe cutaneous melanoma remains
one of the most controversial subjects in the field of surgery and plastic surgery (5,
30, 35-38). Some of the conclusions have been invalidated by the fact that over the
period of review in most cases, improvement in results would be expected due to
more adequate local excision. Also, to date there has been no controlled clinical
investigation on randomly selected cases to determine the difference in actuarial
rates of survival, local recurrence, regional metastases, and distant metastases by
using different methods of treatment. For example, a recent paper (38) concluded
that prophylactic groin dissection increased the survival rate of patients with ma-
lignant melanoma of the lower extremity. Survival rate decreased when done thera-
peutically as opposed to prophylactically. The extension of the radical groin
dissection to include retroperitoneal and pelvic dissections produced no long-term
survivors and increased morbidity. Of 87 patients studied, only 13% were alive at 5
yr, and half of those had ilioinguinal dissections. At 10 yr, only 9% of the patients
were alive. Obviously, it is difficult to make a valid interpretation from this paper.
This is especially true if one reads another publication that concludes that routine
lymphadenectomy for malignant melanoma isjustified neither electively nor thera-
peutically (37).
In order to assess the results oflymph node dissections, patients may be assigned
a clinical stage as well as a histologic level. Clinical Stage I refers to localized mela-
nomas, whether primary or recurrent. Stage II is used for those lesions that have
spread to regional lymph nodes, and Stage III indicates distant metastases.
Another recent article (5) concerns head and neck melanoma. For Clinical Stage
I disease at Level II, 6% ofthelymph nodes were positive with an 86% 10-yr survival
rate; Level III, 29% positive neck nodes and 60% 10-yr survival; Level IV, 32%
positive cervical nodes with a 55% 10-yr survival; and Level V lesions demonstrated
a 63% cervical lymph node metastatic rate with a 44% 10-yr survival. It was con-
cluded that no neck dissections were required for Level I or Level II but that the
patient with a Level V melanoma would benefit from a radical regional neck
dissection. These conclusions were based on Clinical Stage I disease.
CONCLUSIONS
1. Wide local excision and skin grafting is the treatment of choice for malignant
melanoma ofthe skin.
2. Regional lymph node dissection remains controversial, and perhaps immu-
nologic treatment rather than therapeutic lymphadenectomy is indicated for re-
gional nodal metastases.
3. Prophylactic regional lymphadenectomy is possibly indicated in the following
three circumstances: (A) Where a factor of direct anatomic continuity and conti-
guity exists; (B) where the primary lesion recurs and the clinical status ofthedisease
remains Stage I; (C) For Level V, Stage I lesions.
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